Edwards Lifesciences ( NYSE:EW ) First Quarter 2024 Results Key Financial Results Revenue: US$1.60b (up 9.5% from 1Q...
Edwards Lifesciences stock underperformed its peers on Friday, sliding on light sales of its transcatheter aortic heart-valve replacements.
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.